Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer

Joel M. Reid, David C. Stevens, Joseph Rubin, Matthew M. Ames

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

The antitumor activity of temozolomide (TMZ) is believed to arise via formation of the reactive, alkylating metabolite 3-methyl-(triazen-1- yl)imidazole-4-carboximide (MTIC), which is produced by chemical hydrolysis of the parent drug. MTIC has not been quantitated in plasma or urine following administration of TMZ to patients. We developed a sensitive, specific method for the determination of MTIC levels in plasma, based on reverse-phase high-pressure liquid chromatography of the supernatant that is obtained by methanol precipitation of plasma proteins. Due to poor stability under physiological conditions, determination of MTIC required rapid specimen processing, precipitation of plasma proteins with methanol, and storage of the methanolic supernatant at -70°C. The pharmacokinetics of MTIC were studied in 15 patients who received 125-250 mg/m2 TMZ. Peak plasma concentrations of 0.07-0.61 μg/ml MTIC were observed approximately 1 h after a p.o. dose of TMZ. Appearance and disappearance (t( 1/4 ), 88 min) of the reactive metabolite paralleled the appearance and disappearance of TMZ in plasma. The mean values of the metabolite peak plasma concentration and AUC were 2.6% (range, 1.6-4.6%) and 2.2% (range, 0.8-3.6%), respectively, of the values for TMZ. MTIC did not accumulate in plasma following five consecutive daily doses of TMZ.

Original languageEnglish (US)
Pages (from-to)2393-2398
Number of pages6
JournalClinical Cancer Research
Volume3
Issue number12 I
StatePublished - Dec 1 1997

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this